Data on viral hepatitis B (HBV) testing and vaccination in primary care settings among persons at sexual risk for HBV infection have been sparse. We examined rates and factors associated with HBV serologic testing and vaccination rates in adults infected with sexually transmitted infections. We conducted a retrospective cohort study of adults diagnosed with chlamydia, gonorrhea, or syphilis in Kaiser Permanente Southern California in 2008-2011. The vaccine series initiation was examined in subjects who were tested susceptible. The 90-day hepatitis B surface antigen (HBsAg) testing rate was 28.1% in 15 357 adults. Testing rates increased through the study period. Only 8.8% of patients received both HBsAg and hepatitis B surface antibody tests to determine prior exposure and susceptibility to HBV. Among those who were tested susceptible, 116 (10.6%) subjects initiated the vaccine series. In multivariable logistic regression analysis, the odds of receiving testing was inversely associated with female sex, black race, other/unknown race, or having prespecified chronic comorbidities. In survival analysis, adults aged 25-34 years and ≥55 years were more likely to initiate hepatitis B vaccine series compared with those aged 18-24 years. There are missed opportunities in HBV testing and vaccination in primary care. Implementation of provider decision-making support tools in the electronic medical record system may potentially improve hepatitis B testing and vaccination rates.
Viral hepatitis B is a common sexually transmitted infection (STI) that can be prevented by immunization. Hepatitis B vaccination is the most effective measure to prevent hepatitis B virus (HBV) infection and its consequences, including cirrhosis of the liver, liver cancer, liver failure, and death. In the United States, the number of newly acquired HBV infection has declined substantially following the implementation of comprehensive national immunization strategies [1] [2] [3] , especially among children. Although there have been declines in incidence among adults, higher rates of acute HBV infections remain among adults [4, 5] . According to the Centers for Disease Control and Prevention (CDC), there were 8000 new HBV infections in 2010 and an estimated 1.2 million persons living with chronic HBV infection in the United States [6] . Furthermore, a recent meta-analysis suggested that chronic HBV prevalence in the United States may be as high as 2.2 million cases [7] . The most common source of acute, newly acquired HBV among adults in the United States is sexual contact. Heterosexual transmission accounts for approximately 39% of new HBV infections among adults, and approximately 24% of new infections occurred among men who have sex with men, according to the CDC data for 2001-2005 [3] .
To impede ongoing HBV transmission among unvaccinated adults with behavioral risks for HBV transmission, the CDC updated recommendations to increase hepatitis B vaccination of adults at risk [3, 8] .
Persons who acquire STIs are at increased risk of acquiring HBV through sexual transmission and are recommended for HBV testing and vaccination if susceptible. However, suboptimal vaccination acceptance rates have been reported among persons attending sexually transmitted disease (STD) clinics [9] [10] [11] . To date, data on HBV testing practices and vaccination in primary care settings of persons at sexual risk for HBV infection have been sparse. This study examines HBV testing and vaccination practice in adults infected with chlamydia, gonorrhea, or syphilis seeking care in non-STD clinics of a large managed care organization, and explores factors associated with adherence to HBV testing and vaccination recommendations.
METHODS

Study Setting
We conducted a retrospective cohort study among adults enrolled in the Kaiser Permanente Southern California (KPSC) health plan between January 2008-December 2011. KPSC serves >3.5 million members who represent the racially and sociodemographically diverse Southern California population [12] . Compared to the overall US population, the proportion of individuals of Asian descent is twice greater and that of Hispanics is 3 times greater in the KPSC membership. KPSC members are insured though prepaid health plans and receive integrated primary and specialty care. KPSC has employed a complex electronic medical record (EMR) system that captures healthcare encounters in outpatient, inpatient, and emergency department settings and links all laboratory results, procedures, and pharmacy utilization through members' unique medical record number (MRN). Immunization and skin tests are tracked in the Kaiser Immunization Tracking System (KITS), which is linked to the EMR through the MRN. The KITS captures details of all vaccinations administered in Kaiser Permanente facilities, including manufacturer, lot number, dosage, time, and location of vaccination. Vaccines delivered to members outside the health plan were entered into the KITS, with appropriate documentation to substantiate its delivery. History of vaccinations before members joined KPSC are entered into the KITS, with supporting documents provided by the patient. The study protocol was reviewed and approved by the KPSC Institutional Review Board with a waiver of requirement for informed consent.
Study Design
We identified adults who were tested for chlamydia, gonorrhea, or syphilis between 1 January 2008 and 31 December 2011 through EMRs. Subjects who received a positive result for any of the STIs of interest were eligible for inclusion, and only the first positive test result of each patient during the study period was included in the analyses. A syphilis case was defined by positive enzyme immunoassay and rapid plasma reagin titer.
Chlamydia and gonorrhea cases were identified by positive urine or swab test results. The specimen collection date for the first STI test was defined as the index date (baseline). A minimum of 6 months' membership before the index date was required to allow ascertainment of the history of previous hepatitis B vaccination and HBV infections prior to the baseline, comorbidities that are indications for hepatitis B vaccination (ie, diabetes, chronic liver or kidney diseases), and healthcare utilization pattern. Subjects were excluded from the analyses if they had a documented hepatitis B vaccination in KITS, previous laboratory evidence of HBV 3), or liver cancer (ICD-9 code 155.0) any time prior to the baseline. The information of age at baseline, sex, and race/ethnicity was ascertained through membership records. History of diagnosis for diabetes, chronic liver disease, and chronic kidney disease were identified by ICD-9 codes 250, 571, and 585, respectively.
The main outcomes of interest were (1) HBV cotesting (on day 0, same day as STI testing) and the 90-day testing rate (including day 0) following the STI test; and (2) time to hepatitis B vaccine series initiation among subjects who were tested for HBV infection and determined to be susceptible. Subjects were considered tested for HBV infection if a test for HBsAg was performed. Subjects were considered susceptible for HBV infection if both HBsAg and HBsAb test results were negative. All susceptible subjects were followed from the time of HBV serologic tests until the time of initiation of the hepatitis B vaccine series, termination of KPSC membership, death, or 31 December 2012, whichever came first.
Statistical Analysis
We calculated the proportion of subjects who were tested for HBsAg on the same date (day 0, cotesting) of the STI testing, as well as the proportion of subjects who were tested within 90 days (90-day testing, including day 0) following the STI test. The proportion of subjects who received HBsAg and/or HBsAb tests was calculated for the overall sample and by age, sex, and race/ethnicity. The rate of hepatitis B vaccine series initiation was calculated among subjects who were determined susceptible for HBV infection, defined as having negative HBsAg and HBsAb results.
We conducted χ 2 tests (for categorical variables) to compare the distribution of sociodemographic characteristics between tested and untested subjects and between vaccinated and unvaccinated susceptible subjects. Logistic regression models were used to identify factors associated with 90-day testing rate. Cox proportional hazards regression models were used to identify factors associated with time to hepatitis B vaccine series initiation among those tested susceptible for HBV infection. All multivariable analyses were adjusted for membership length prior to the baseline, and number of outpatient visits within 6 months prior to the baseline. All analyses were performed using SAS Enterprise Guide version 4.2 (SAS Institute, Cary, North Carolina).
RESULTS
A total of 15 357 adults with a positive test result for any of the prespecified STIs during January 2008-December 2011 were included in the analyses, including 9910 (64.5%) women and 5447 (35.5%) men. The number of subjects who received serologic testing for active HBV infection and susceptibility (HBsAg and HBsAb), and the number of susceptible subjects who received HBV vaccination, are shown in Figure 1 . The baseline characteristics and HBV testing rates by demographics and calendar year of the STI testing are presented in Table 1 . The majority of the adults were young at the time of STI diagnosis (35.2% were 18-24 years and 39.0% were 25-34 years), and a large proportion of the subjects were Hispanic (40.8% [n = 6270]). Almost half (42.9%) of the subjects had no outpatient visit during the 6 months prior to STI testing. The overall HBsAg testing rate was 28.1% (n = 4309) within the 90 days following the index STI test, with 2635 (17.2%) subjects cotested for HBsAg on the same date of the STI testing (Table 1 ). In general, the HBsAg testing rate was higher in subjects aged 25-34 years and in male subjects, and it was lower in black subjects (P < .0001). Interestingly, compared with male subjects, the HBsAg cotesting rate was much lower in women than in men (13.5% vs 23.9%), even though the 90-day testing rates in the 2 groups were relatively similar (27.0% vs 30.1%, respectively). Compared to subjects of other race/ethnicity, black subjects had a significantly lower HBV cotesting rate (14 Among the 1096 susceptible subjects who were tested negative for both HBsAg and HBsAb, only 10.6% (n = 116) initiated the hepatitis B vaccine series during the follow-up period. In addition, only 2.6% (n = 280) of those who had no serological testing initiated the hepatitis B vaccine series. The vaccine initiation rates by patient characteristics for those who were tested susceptible are presented in Table 2 . The vaccine initiation rate was higher in those who were ≥55 years (19.5%) and those who had ≥2 outpatient visits during the 6 months prior to the index STI testing (12.9%), and it was much lower among blacks (7.7%) and Hispanics (9.3%).
In multivariable logistic regression models, after adjustment for covariates, the odds of receiving HBsAg testing within 90 days following the index STI was inversely associated with female sex, black race, other/unknown race, or having prespecified chronic comorbidities (female vs male: odds ratio Among persons who were tested susceptible for HBV infection, age at baseline was statistically significantly associated with the likelihood of vaccine initiation. In multivariable Cox proportional hazards regression models (Table 3) [95% CI, 1.11-3.19]; ≥55 years: HR = 2.99 [95% CI, 1.18-7.61]). Sex, race/ethnicity, index STI testing year, and having prespecified chronic comorbidities were not associated with vaccine initiation after adjustment for other covariates.
DISCUSSION
In this study, we found that <30% of the subjects were screened for active HBV infection (HBsAg) within 90 days following a STI diagnosis in this insured population who received primary care in a non-STD clinic setting, although the testing rate increased slightly each year, from 24.7% in 2008 to 30.3% in 2011. Only 8.8% of the subjects received both HBsAg and HBsAb testing for evaluation for vaccination need. Among those whose results indicated susceptible for HBV infection, only about 11% initiated the hepatitis B vaccine series. These figures are relatively lower than the testing and vaccination rates observed in STD clinics (approximately 52% testing rate, 25%-56% vaccination rate) that serve primarily high-risk populations [13] [14] [15] .
HBsAg testing and vaccination rates were significantly lower among adults of black race compared to whites. This has important public health implications on the targeted intervention effort, because surveillance data suggest that non-Hispanic blacks remain at increased risk of HBV infection many years following the introduction of hepatitis B vaccine [5, 16, 17] . Racial/ethnic disparities in the incidence of acute HBV for Asians/Pacific Islanders, American Indians/Alaska Natives, and Hispanics were nearly eliminated. The incidence among blacks, however, remained nearly 3-4 times higher than that among other racial/ethnic populations [5, 17] . Given that black men and women are also disproportionately affected by STIs and HIV infection [18, 19] , low HBV testing rates among blacks may add to the disparity in increased risk of sexual transmission of HBV and hepatic morbidity and mortality due to untreated chronic HBV coinfection in non-Hispanic blacks. We also observed a higher testing rate in men vs women, which is consistent with the relatively higher acute HBV incidence rate among males than in females in the general population. In 2010, the incidence rate of HBV infection in males was approximately 1.6 times higher than that for females in the United States [17] . Persons who were 25-34 years old were more likely to be tested for HBsAg, and the odds of vaccine initiation was higher among those who were 25-34 or ≥55 years old, compared to those aged 18-24 years. This association is consistent with the risk of acute HBV by age: the highest acute HBV incidence rate in persons aged 30-39 years, the lowest acute HBV incidence rate in adolescents and children aged ≤19 years, and the highest mortality rates observed among persons aged 55-64 years in the United States [17] . The testing rate was lower among adults aged 18-24 years than older adults (except for those aged 45-54 years). As the Advisory Committee on Immunization Practices issued the recommendation of universal childhood hepatitis B vaccination in 1991 [1] , it is possible that many of those younger adults may have received the childhood hepatitis B vaccine series before they enrolled in the KPSC health plan and informed their providers, but lack documentation in KITS. The higher vaccination rate among older adults might be partially explained by a greater opportunity for vaccination because older members generally visit clinics more frequently than younger members. However, we have adjusted for the number of outpatient visits within 6 months prior to the baseline in the multivariable models to account for the impact of healthcare utilization pattern, and older age remained associated with vaccine initiation.
Although our results suggest that physicians are testing adults based on some risk factors such as age and sex, the general low testing rate among subjects diagnosed with STIs (chlamydia, gonorrhea, or syphilis) is particularly concerning because our results suggest that a large proportion of primary care providers are not fully aware that persons infected with STIs are also at high risk of HBV acquisition. Low rates of testing for active HBV infection (HBsAg) in adults with STI diagnoses in primary care settings represent a missed opportunity for identifying persons who can benefit from hepatitis B treatment. In a CDC study of 760 adults with reported acute hepatitis B during 2001-2004, 39% reported a history of STI treatment [20] .
In this study, only a small proportion of subjects (8.8%) were tested for both HBsAg and HBsAb to determine susceptibility. This finding suggests that healthcare providers do not frequently identify candidates for hepatitis B vaccination as part of routine clinical services, even though hepatitis B vaccination is recommended for persons seeking STI evaluation or care. Because serologic testing before vaccination is not required, we also examined the vaccine initiation rate among those who did not receive any HBV serologic testing and found that only 2.6% of these subjects initiated the vaccine series. Furthermore, among those who were identified as susceptible, only about 11% initiated the hepatitis B vaccination series. Universal vaccination of adults in settings such as STD treatment facilities or those serving injection drug users will reach a substantial proportion of all adults at risk for HBV infection. However, not all adults with risk factors for acute HBV infection visit those settings. An estimated 75% of STIs are diagnosed in settings other than STD clinics [21] . Therefore, it is extremely important for providers in primary care settings to screen for HBV infection and identify candidates for hepatitis B vaccination. We initially postulated that subjects who had diabetes or chronic liver or kidney diseases would be more likely to be tested because those conditions are indications for hepatitis B vaccination. However, our results suggest that having any of those conditions was associated with decreased odds of being tested for HBV. It is likely that providers primarily focus on treating those conditions during the clinical encounters when they are often constrained by the limited appointment time. This finding suggests that strategies (eg, education and training of physicians, alert system, and standing orders) are needed to prompt providers to offer hepatitis B testing and vaccination for adults at risk for sexual acquisition of HBV. Indeed, our organization is currently embarking on these strategies. The strength of this study is that we efficiently used an EMR database to identify a large cohort of adults who were diagnosed with STIs and followed up on their HBV testing and vaccination status, which avoids the problem of potential selection bias (due to nonparticipation) and high attrition that often occurs in survey studies. By utilizing the integrated EMR database to ascertain STI test results, HBV serologic tests, and hepatitis B vaccination status, we minimized recall bias that often plagues survey studies using self-reported data. One limitation, however, is our inability to ascertain complete history of hepatitis B vaccination and chronic hepatitis B infection that occurred before a person's enrollment at KPSC. Even though the minimum 6-month membership prior to the baseline allowed us to ascertain this information through coding in the EMR to some extent, we still might not capture the complete medical history if someone recently enrolled in KPSC prior to the STI diagnosis, although some information might be recorded in the clinical notes but not coded. There are missed opportunities in primary care for testing of active HBV infection as well as identifying candidates for HBV vaccination in adults seeking evaluation and care for STIs. Implementation of targeted clinical decision-making support tools in the EMR system may potentially improve hepatitis B testing and vaccination rates.
Notes
